Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -12,6 +12,10 @@
12	12
13	13	Sun Pharma has 44 manufacturing sites approved by global health regulatory agencies—supported by a worldwide supply chain—and multiple research and development (R&D) facilities across the world, investing 6.9% of its sales in R&D. It has a diverse employee base of 32,000+ individuals across 50 nationalities worldwide.
14	14
	15	+
	16	+[[image:SUNPHARMA.jpg]]
	17	+
	18	+
15	15	= Business Overview =
16	16
17	17	== Research & Development ==
...	...	@@ -181,6 +181,19 @@
181	181
182	182	Sun Pharmaceutical has a comprehensive product offering in the US market consisting of approved ANDAs for 483 products while filings for 98 ANDAs await US FDA approval, including 20 tentative approvals. For the quarter, 6 ANDAs were filed and 2 approvals were received. Additionally, the pipeline includes 55 approved NDAs await US FDA approval.
183	183
	188	+
	189	+= Recent developments =
	190	+
	191	+**Sun Pharma Consolidated December 2020 Net Sales at Rs 8,836.78 crore, up 8.36% Y-o-Y **{{footnote}}https://www.moneycontrol.com/news/business/earnings/sun-pharma-consolidated-december-2020-net-sales-at-rs-8836-78-crore-up-8-36-y-o-y-6432631.html{{/footnote}}
	192	+
	193	+**February 02, 2021**; Reported Consolidated quarterly numbers for Sun Pharmaceutical Industries are:
	194	+
	195	+* Net Sales at Rs 8,836.78 crore in December 2020 up 8.36% from Rs. 8,154.85 crore in December 2019.
	196	+* Quarterly Net Profit at Rs. 1,913.41 crore in December 2020 up 87.7% from Rs. 1,019.38 crore in December 2019.
	197	+* EBITDA stands at Rs. 2,721.09 crore in December 2020 up 38.74% from Rs. 1,961.28 crore in December 2019.
	198	+* Sun Pharma EPS has increased to Rs. 7.72 in December 2020 from Rs. 3.81 in December 2019.
	199	+
	200	+
184	184	= References =
185	185
186	186	{{putFootnotes/}}